Document is current
Any future updates will be listed below
-
Authors
Canepari, Cesare
Milani, Michela https://orcid.org/0000-0002-0363-678X
Simoni, Chiara https://orcid.org/0000-0003-0138-2197
Starinieri, Francesco
Volpin, Monica https://orcid.org/0000-0002-0794-9900
Fabiano, Anna https://orcid.org/0000-0002-7604-6967
Biffi, Mauro https://orcid.org/0000-0002-6914-2854
Russo, Fabio
Norata, Rossana
Rocchi, Martina
Brombin, Chiara
Cugnata, Federica
Montini, Eugenio https://orcid.org/0000-0003-1771-6067
Sanvito, Francesca https://orcid.org/0000-0002-4046-8420
Grompe, Markus https://orcid.org/0000-0002-6616-4345
Cantore, Alessio https://orcid.org/0000-0002-9741-997X
-
Funding
Funding for this research was provided by:
Fondazione Telethon (TTACC0422TT)
- License Information
-
More Information
Article History
Received: 1 July 2024
Accepted: 12 May 2025
First Online: 23 May 2025
Competing interests
: C.C. and A.C. are inventors on patent applications submitted by Fondazione Telethon, San Raffaele Scientific Institute, on LV technology related to the work presented in this manuscript. Fondazione Telethon and San Raffaele Scientific Institute, through SR-Tiget, have established a research collaboration on liver-directed LV gene therapy of hemophilia with GeneSpire. The remaining authors declare no competing interests.
